4//SEC Filing
ENANTA PHARMACEUTICALS INC 4
Accession 0000908662-13-000163
$ENTACIK 0001177648operating
Filed
Mar 27, 8:00 PM ET
Accepted
Mar 28, 4:26 PM ET
Size
22.7 KB
Accession
0000908662-13-000163
Insider Transaction Report
Form 4
AFTING ERNST-GUNTER
Director
Transactions
- Conversion
Common Stock
2013-03-26+97→ 21,072 total - Conversion
Common Stock
2013-03-26+11,215→ 32,287 total - Conversion
Series C Convertible Preferred Stock
2013-03-26−2,906→ 0 total→ Common Stock (674 underlying) - Conversion
Common Stock
2013-03-26+674→ 20,975 total - Conversion
Series G-2 Convertible Preferred Stock
2013-03-26−48,337→ 0 total→ Common Stock (11,215 underlying) - Conversion
Series B Convertible Preferred Stock
2013-03-26−10,000→ 0 total→ Common Stock (2,320 underlying) - Conversion
Series E Convertible Preferred Stock
2013-03-26−320→ 0 total→ Common Stock (97 underlying) - Conversion
Common Stock
2013-03-26+2,320→ 20,301 total - Conversion
Common Stock
2013-03-26+2,320→ 17,981 total - Conversion
Series A Convertible Preferred Stock
2013-03-26−10,000→ 0 total→ Common Stock (2,320 underlying)
Footnotes (5)
- [F1]The Series A Convertible Preferred Stock has no expiration date, and each share of Series A Convertible Preferred Stock converted automatically into approximately 0.23202 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
- [F2]The Series B Convertible Preferred Stock has no expiration date, and each share of Series B Convertible Preferred Stock converted automatically into approximately 0.23202 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
- [F3]The Series C Convertible Preferred Stock has no expiration date, and each share of Series C Convertible Preferred Stock converted automatically into approximately 0.23202 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
- [F4]The Series E Convertible Preferred Stock has no expiration date, and each share of Series E Convertible Preferred Stock converted automatically into approximately 0.30529 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
- [F5]The Series G-2 Convertible Preferred Stock has no expiration date, and each share of Series G-2 Convertible Preferred Stock converted automatically into approximately 0.23202 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
Documents
Issuer
ENANTA PHARMACEUTICALS INC
CIK 0001177648
Entity typeoperating
Related Parties
1- filerCIK 0001177648
Filing Metadata
- Form type
- 4
- Filed
- Mar 27, 8:00 PM ET
- Accepted
- Mar 28, 4:26 PM ET
- Size
- 22.7 KB